Concepts (75)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 3 | 2023 | 24 | 2.270 |
Why?
|
| Coronary Artery Disease | 3 | 2023 | 132 | 1.470 |
Why?
|
| Drug-Eluting Stents | 2 | 2022 | 17 | 1.470 |
Why?
|
| Myocardial Perfusion Imaging | 4 | 2021 | 71 | 1.280 |
Why?
|
| Myocardial Infarction | 3 | 2022 | 132 | 0.900 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2023 | 8 | 0.830 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2023 | 17 | 0.820 |
Why?
|
| Aortic Valve Stenosis | 1 | 2023 | 20 | 0.810 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2023 | 25 | 0.810 |
Why?
|
| Hypotension | 1 | 2022 | 25 | 0.800 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2022 | 33 | 0.790 |
Why?
|
| Coronary Artery Bypass | 1 | 2022 | 25 | 0.760 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2022 | 2 | 0.760 |
Why?
|
| Thrombosis | 1 | 2022 | 54 | 0.730 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 63 | 0.720 |
Why?
|
| Conservative Treatment | 1 | 2021 | 20 | 0.700 |
Why?
|
| Heart Failure | 1 | 2022 | 149 | 0.700 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 44 | 0.680 |
Why?
|
| Kidney Failure, Chronic | 2 | 2017 | 127 | 0.620 |
Why?
|
| Network Meta-Analysis | 3 | 2023 | 32 | 0.600 |
Why?
|
| Treatment Outcome | 7 | 2023 | 3540 | 0.570 |
Why?
|
| Adenosine A2 Receptor Agonists | 1 | 2017 | 15 | 0.540 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2017 | 79 | 0.540 |
Why?
|
| Purines | 1 | 2017 | 43 | 0.530 |
Why?
|
| Pyrazoles | 1 | 2017 | 61 | 0.520 |
Why?
|
| Humans | 13 | 2023 | 27307 | 0.420 |
Why?
|
| Risk Factors | 5 | 2023 | 2335 | 0.410 |
Why?
|
| Bayes Theorem | 2 | 2023 | 42 | 0.410 |
Why?
|
| Death | 2 | 2023 | 47 | 0.400 |
Why?
|
| Kidney Transplantation | 3 | 2020 | 119 | 0.390 |
Why?
|
| Prognosis | 4 | 2021 | 808 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 291 | 0.300 |
Why?
|
| Stroke Volume | 2 | 2022 | 50 | 0.250 |
Why?
|
| Tomography, Optical Coherence | 1 | 2023 | 15 | 0.210 |
Why?
|
| Aortic Valve | 1 | 2023 | 24 | 0.210 |
Why?
|
| Coronary Angiography | 1 | 2023 | 73 | 0.200 |
Why?
|
| Receptors, Angiotensin | 1 | 2022 | 4 | 0.200 |
Why?
|
| Neprilysin | 1 | 2022 | 11 | 0.200 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 8 | 0.200 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 18 | 0.200 |
Why?
|
| Ultrasonography, Interventional | 1 | 2023 | 71 | 0.200 |
Why?
|
| Male | 5 | 2022 | 14887 | 0.200 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 54 | 0.190 |
Why?
|
| Female | 5 | 2022 | 15334 | 0.190 |
Why?
|
| Cardiomyopathies | 1 | 2022 | 28 | 0.190 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2022 | 47 | 0.190 |
Why?
|
| Tachycardia, Ventricular | 1 | 2022 | 23 | 0.190 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 478 | 0.190 |
Why?
|
| Drug Therapy, Combination | 1 | 2022 | 168 | 0.190 |
Why?
|
| Hemorrhage | 1 | 2022 | 82 | 0.190 |
Why?
|
| Catheter Ablation | 1 | 2022 | 62 | 0.190 |
Why?
|
| Observational Studies as Topic | 2 | 2022 | 21 | 0.190 |
Why?
|
| Risk Assessment | 2 | 2021 | 631 | 0.180 |
Why?
|
| Heart Valve Diseases | 1 | 2020 | 14 | 0.170 |
Why?
|
| Mitral Valve | 1 | 2020 | 9 | 0.170 |
Why?
|
| Calcinosis | 1 | 2020 | 44 | 0.160 |
Why?
|
| Exercise Test | 2 | 2017 | 121 | 0.160 |
Why?
|
| Vasodilator Agents | 1 | 2017 | 31 | 0.140 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 16 | 0.140 |
Why?
|
| Aminophylline | 1 | 2017 | 12 | 0.140 |
Why?
|
| Critical Pathways | 1 | 2017 | 20 | 0.140 |
Why?
|
| Heart Rate | 1 | 2017 | 112 | 0.130 |
Why?
|
| Patient Safety | 1 | 2017 | 38 | 0.130 |
Why?
|
| Risk | 1 | 2017 | 205 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2017 | 86 | 0.130 |
Why?
|
| Comorbidity | 1 | 2017 | 488 | 0.120 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 4841 | 0.090 |
Why?
|
| Aged | 2 | 2021 | 9120 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2020 | 3551 | 0.060 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2022 | 33 | 0.050 |
Why?
|
| Recurrence | 1 | 2022 | 309 | 0.050 |
Why?
|
| Echocardiography | 1 | 2020 | 74 | 0.040 |
Why?
|
| Incidence | 1 | 2020 | 763 | 0.030 |
Why?
|
| Middle Aged | 2 | 2020 | 9068 | 0.030 |
Why?
|
| United States | 1 | 2020 | 2078 | 0.030 |
Why?
|